Director of ChromaDex Co. (NASDAQ:CDXC) Kristin Patrick sells 23,000 shares

ChromaDex Co. (NASDAQ:CDXC – Get Your Free Report ) Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this hyperlink.

ChromaDex price performance

Shares of NASDAQ CDXC opened at $3.50 on Tuesday. The company has a 50-day simple moving average of $2.88 and a 200-day simple moving average of $2.92. The company has a market cap of $264.39 million, a PE ratio of -70.00 and a beta of 1.87. ChromaDex Co. has a 12-month low of $1.25 and a 12-month high of $4.65.

Analyst upgrades and downgrades

Several research analysts recently issued reports on CDXC shares. Roth Mkm restated a “buy” rating and set a $6.00 price objective on shares of ChromaDex in a research report on Wednesday, June 12th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a research report on Friday, August 9th.

Check out our latest research report on CDXC

Institutional trading of ChromaDex

Hedge funds have recently bought and sold shares of the company. Miracle Mile Advisors LLC acquired a new position in ChromaDex in the second quarter valued at $27,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex in the second quarter valued at $31,000. Merriman Wealth Management LLC purchased a new position in ChromaDex in the second quarter valued at $32,000. Lazard Asset Management LLC purchased a new position in ChromaDex in the 1st quarter worth about $43,000. Finally, SG Americas Securities LLC acquired a new stake in ChromaDex in the 1st quarter worth approximately $54,000. Institutional investors and hedge funds own 15.41% of the company’s shares.

ChromaDex Company Profile

(Get a free report)

ChromaDex Corporation operates as a bioscience company focused on developing products for healthy aging. The company operates through three segments: Consumer Products; Ingredients; and Reference Analytical Standards and Services. Research nicotinamide adenine dinucleotide (NAD+); supplies finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary ingredient technologies and supplies these ingredients as raw materials to consumer product manufacturers.

Further reading

Get news and reviews for ChromaDex Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChromaDex and related companies with MarketBeat.com’s FREE daily email newsletter.